These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10213526)

  • 1. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies.
    Blum RA; Kazierad DJ; Tenero DM
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):79S-85S. PubMed ID: 10213526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The renal profile of eprosartan.
    Sica DA; Hollenberg NK
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):86S-94S. PubMed ID: 10213527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of eprosartan: a new angiotensin II receptor antagonist. Summary.
    Sica DA
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):108S-109S. PubMed ID: 10213530
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.
    Tenero DM; Martin DE; Ilson BE; Boyle DA; Boike SC; Carr AM; Lundberg DE; Jorkasky DK
    Ann Pharmacother; 1998 Mar; 32(3):304-8. PubMed ID: 9533060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
    Martin DE; DeCherney GS; Ilson BE; Jones BA; Boike SC; Freed MI; Jorkasky DK
    J Clin Pharmacol; 1997 Feb; 37(2):155-9. PubMed ID: 9055142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eprosartan.
    McClellan KJ; Balfour JA
    Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.
    Martin DE; Tompson D; Boike SC; Tenero D; Ilson B; Citerone D; Jorkasky DK
    Br J Clin Pharmacol; 1997 Jun; 43(6):661-4. PubMed ID: 9205830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eprosartan does not affect the pharmacodynamics of warfarin.
    Kazierad DJ; Martin DE; Ilson B; Boike S; Zariffa N; Forrest A; Jorkasky DK
    J Clin Pharmacol; 1998 Jul; 38(7):649-53. PubMed ID: 9702851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eprosartan: a review of its use in the management of hypertension.
    Plosker GL; Foster RH
    Drugs; 2000 Jul; 60(1):177-201. PubMed ID: 10929934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.
    Muders F; Palkovits M; Bahner U; Kirst I; Elsner D; Jandeleit-Dahm K
    Pharmacol Res; 2001 Mar; 43(3):251-5. PubMed ID: 11401417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose proportionality study of eprosartan in healthy male volunteers.
    Chapelsky MC; Martin DE; Tenero DM; Ilson BE; Boike SC; Etheredge R; Jorkasky DK
    J Clin Pharmacol; 1998 Jan; 38(1):34-9. PubMed ID: 9597557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension.
    Ilson BE; Martin DE; Boike SC; Jorkasky DK
    J Clin Pharmacol; 1998 May; 38(5):437-41. PubMed ID: 9602957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical profile of the angiotensin II receptor blocker eprosartan.
    Hedner T
    J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
    Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profile of eprosartan.
    Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
    Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
    Kazierad DJ; Martin DE; Blum RA; Tenero DM; Ilson B; Boike SC; Etheredge R; Jorkasky DK
    Clin Pharmacol Ther; 1997 Oct; 62(4):417-25. PubMed ID: 9357393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.
    Kovacs SJ; Tenero DM; Martin DE; Ilson BE; Jorkasky DK
    Pharmacotherapy; 1999 May; 19(5):612-9. PubMed ID: 10331824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients.
    van Rijn-Bikker PC; Ackaert O; Snelder N; van Hest RM; Ploeger BA; Koopmans RP; Mathôt RA
    Clin Pharmacokinet; 2013 Sep; 52(9):793-803. PubMed ID: 23696281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of eprosartan: a new angiotensin II receptor antagonist. Introduction.
    Hollenberg NK
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):71S-72S. PubMed ID: 10213524
    [No Abstract]   [Full Text] [Related]  

  • 20. Eprosartan: a review of its use in hypertension.
    Plosker GL
    Drugs; 2009; 69(17):2477-99. PubMed ID: 19911859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.